Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML4ZOT)

Drug Name

Lidocaine Drug Info

Synonyms

Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide

Indication

Disease Entry	ICD 11	Status	REF
Anaesthesia	9A78.6	Approved	[1]
Carpal tunnel syndrome		Approved	[2]
Interstitial cystitis	GC00.3	Approved	[2]
Long QT syndrome	BC65.0	Approved	[2]
Pain	MG30-MG3Z	Approved	[2]
Pediculus capitis infestation	1G00.0	Approved	[2]
Periodontitis	DA0C	Approved	[2]
Postherpetic neuralgia	1E91.5	Approved	[2]
Pthirus pubis infestation		Approved	[2]
Dysmenorrhea	GA34.3	Phase 2	[3]
Chronic pain	MG30	Investigative	[2]
Neuralgia		Investigative	[2]
Premature ejaculation	HA03.0Z	Investigative	[2]
Pruritus	EC90	Investigative	[2]

Therapeutic Class

Anesthetics

Cross-matching ID

PubChem CID: 3676
ChEBI ID: CHEMBL79
CAS Number: CAS 137-58-6
TTD Drug ID: DML4ZOT
VARIDT Drug ID: DR00849
INTEDE Drug ID: DR0953

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

DME

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.9 (SCN11A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[18]
Lacosamide	DMVM6QR	Convulsion	8A68.Z	Approved	[19]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[20]
Tolperisone	DMA2GHJ	Muscle spasm	MB47.3	Approved	[21]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[22]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[19]
Oxcarbazepine	DM5PU6O	Epilepsy	8A60-8A68	Approved	[23]
HP-184	DMNOMV2	Multiple sclerosis	8A40	Phase 2	[24]
QX-314	DMAV2FM	Pain	MG30-MG3Z	Terminated	[25]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[5]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[29]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[5]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[5]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[30]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[5]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[32]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[33]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[34]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[35]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[36]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[37]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[38]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[39]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[40]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[34]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[41]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[42]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[43]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[44]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[45]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[46]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[47]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[39]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[48]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[49]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[50]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[42]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[8]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[37]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[8]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Metronidazole	DMTIVEN	Abscess		Approved	[53]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[54]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[55]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[56]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[57]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[58]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[37]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[41]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[59]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[60]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[61]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[62]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[63]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[65]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[66]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[10]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[67]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[68]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[69]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[70]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[71]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[72]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[10]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[10]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[8]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[73]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[10]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[10]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[10]
Metronidazole	DMTIVEN	Abscess		Approved	[53]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2C18 (CYP2C18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[8]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[74]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[54]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[76]
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[77]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[78]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[79]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[80]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[42]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[81]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[81]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[8]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[82]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[83]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[84]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[81]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[85]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[54]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[86]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[87]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[88]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[8]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[89]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[8]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[90]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[91]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[93]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[94]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[8]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[95]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[88]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[11]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[96]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[97]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[98]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[99]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[100]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Alpha-1-acid glycoprotein 1 (ORM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[101]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[102]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[103]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[13]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[104]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[104]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[105]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[107]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By C-reactive protein (CRP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[108]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[109]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[111]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[112]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[113]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[114]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[115]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[116]
Milrinone	DM8TUPF	Congestive heart failure	BD10	Approved	[117]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Alkaline phosphatase, placental type (ALPP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paricalcitol	DMYBV3G	Hyperparathyroidism	5A51	Approved	[12]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[118]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[119]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[120]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[121]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[122]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[123]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[124]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[125]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[15]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[15]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[126]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[127]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[128]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[15]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[15]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[15]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[129]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[130]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Neurofilament medium polypeptide (NEFM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[131]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[132]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[133]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[134]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[135]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[136]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[137]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[138]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[139]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Alpha-1-acid glycoprotein 2 (ORM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[13]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[101]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[102]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[103]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[13]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[13]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[104]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[104]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Neuronatin (NNAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[134]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[141]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[142]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[143]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[144]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[145]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[139]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[146]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[147]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[148]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Transient receptor potential cation channel subfamily V member 1 (TRPV1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[149]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[150]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[101]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[105]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[140]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[151]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[136]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[152]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[153]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[154]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Sodium channel protein type 5 subunit alpha (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[12]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[155]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[156]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[157]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[158]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[159]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[160]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[161]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[146]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[162]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.9 (SCN11A)	TTN9VTF	SCNBA_HUMAN	Blocker	[4]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[7]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[8]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[9]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[11]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[8]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[10]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alkaline phosphatase, placental type (ALPP)	OTZU4G9W	PPB1_HUMAN	Drug Response	[12]
Alpha-1-acid glycoprotein 1 (ORM1)	OTZKSBRE	A1AG1_HUMAN	Protein Interaction/Cellular Processes	[13]
Alpha-1-acid glycoprotein 2 (ORM2)	OTRJGZP8	A1AG2_HUMAN	Protein Interaction/Cellular Processes	[13]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Drug Response	[12]
Neurofilament medium polypeptide (NEFM)	OT8VCBNF	NFM_HUMAN	Gene/Protein Processing	[14]
Neuronatin (NNAT)	OTNRLO7G	NNAT_HUMAN	Gene/Protein Processing	[14]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[15]
Sodium channel protein type 5 subunit alpha (SCN5A)	OTGYZWR6	SCN5A_HUMAN	Drug Response	[16]
Transient receptor potential cation channel subfamily V member 1 (TRPV1)	OTHHDR03	TRPV1_HUMAN	Gene/Protein Processing	[17]
Ubiquitin carboxyl-terminal hydrolase isozyme L1	OTTCHLRJ	UCHL1_HUMAN	Gene/Protein Processing	[14]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2623).
2	Lidocaine FDA Label
3	ClinicalTrials.gov (NCT00651313) Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods). U.S. National Institutes of Health.
4	Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
5	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
6	Pharmacokinetics of lidocaine hydrochloride metabolized by CYP3A4 in Chinese Han volunteers living at low altitude and in native Han and Tibetan Chinese volunteers living at high altitude. Pharmacology. 2016;97(3-4):107-13.
7	Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.
8	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
9	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
10	Drug Interactions Flockhart Table
11	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
12	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
13	Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. doi: 10.1097/00008571-199610000-00004.
14	Lidocaine prevents breast cancer growth by targeting neuronatin to inhibit nerve fibers formation. J Toxicol Sci. 2021;46(7):329-339. doi: 10.2131/jts.46.329.
15	Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
16	Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. Circ Res. 2008 Aug 15;103(4):396-404. doi: 10.1161/CIRCRESAHA.108.172619. Epub 2008 Jul 3.
17	The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. J Clin Invest. 2008 Feb;118(2):763-76. doi: 10.1172/JCI32751.
18	The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
19	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
20	Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
21	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
22	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
23	Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
24	Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
25	Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
26	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
27	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
28	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
29	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
30	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
31	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
32	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
33	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
34	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
35	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
36	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
37	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
38	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
39	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
40	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
41	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
42	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
43	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
44	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
45	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
46	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
47	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
48	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
49	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
50	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
51	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
52	Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
53	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
54	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
55	CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
56	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
57	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
58	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
59	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
60	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
61	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
62	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
63	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
64	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
65	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
66	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
67	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
68	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
69	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
70	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
71	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
72	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
73	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
74	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
75	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
76	Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
77	Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
78	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
79	Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
80	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
81	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
82	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
83	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
84	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
85	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
86	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
87	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
88	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
89	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
90	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
91	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
92	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
93	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
94	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
95	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
96	Drugs that may have potential CYP2B6 interactions.
97	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
98	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
99	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
100	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
101	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
102	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
103	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
104	Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
105	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
106	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
107	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
108	C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004 Dec 3;18(18):2434-7.
109	Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
110	The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9.
111	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
112	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
113	The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):286-97. doi: 10.1185/03007997509114779.
114	Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology. 2001 May;120(6):1567-8. doi: 10.1053/gast.2001.24495.
115	Effects of hormone treatment on hemostasis variables. Climacteric. 2007 Oct;10 Suppl 2:32-7. doi: 10.1080/13697130701598548.
116	The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
117	The efficacy of preemptive Milrinone or Amrinone therapy in patients undergoing coronary artery bypass grafting. Anesth Analg. 2002 Jan;94(1):22-30, table of contents. doi: 10.1097/00000539-200201000-00005.
118	Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
119	Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
120	Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
121	The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
122	The effects of desmethylimipramine on cyclic AMP-stimulated gene transcription in a model cell system. Biochem Pharmacol. 2005 Sep 1;70(5):762-9. doi: 10.1016/j.bcp.2005.06.012.
123	The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
124	Ornithine decarboxylase antizyme upregulates DNA-dependent protein kinase and enhances the nonhomologous end-joining repair of DNA double-strand breaks in human oral cancer cells. Biochemistry. 2007 Aug 7;46(31):8920-32. doi: 10.1021/bi7000328. Epub 2007 Jul 14.
125	Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
126	Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
127	Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
128	Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
129	Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
130	Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
131	Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
132	DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
133	Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
134	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
135	Valproate reversibly reduces neurite outgrowth by human SY5Y neuroblastoma cells. Brain Res. 2009 Dec 11;1302:21-33. doi: 10.1016/j.brainres.2009.09.051. Epub 2009 Sep 18.
136	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
137	Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
138	Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
139	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
140	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
141	Effects of valproic acid on gene expression during human embryonic stem cell differentiation into neurons. J Toxicol Sci. 2014 Jun;39(3):383-90. doi: 10.2131/jts.39.383.
142	Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
143	Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
144	Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
145	High expressions of neuronatin isoforms in favorable neuroblastoma. J Pediatr Hematol Oncol. 2007 Aug;29(8):551-6. doi: 10.1097/MPH.0b013e3181256b7b.
146	Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
147	Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
148	Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci. 2002 Mar 1;70(15):1821-39.
149	Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001 Oct;134(4):845-52. doi: 10.1038/sj.bjp.0704327.
150	Comparison of protective effect of ascorbic acid on redox and endocannabinoid systems interactions in in vitro cultured human skin fibroblasts exposed to UV radiation and hydrogen peroxide. Arch Dermatol Res. 2017 May;309(4):285-303. doi: 10.1007/s00403-017-1729-0. Epub 2017 Mar 11.
151	Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
152	The anthelminthic drug praziquantel is a selective agonist of the sensory transient receptor potential melastatin type 8 channel. Toxicol Appl Pharmacol. 2017 Dec 1;336:55-65. doi: 10.1016/j.taap.2017.10.012. Epub 2017 Oct 18.
153	Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004 Mar;13(3):129-39. doi: 10.1111/j.0906-6705.2004.0178.x.
154	Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol. 2018 Apr;92(4):1507-1524.
155	Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
156	Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):338-41. doi: 10.1046/j.1460-9592.2003.00045.x.
157	Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
158	Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
159	Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
160	Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
161	Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
162	Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.